XML 41 R17.htm IDEA: XBRL DOCUMENT
v3.20.1

Common Stock | 12 Months Ended
--- | ---
Dec. 31, 2019
Equity [Abstract] |
Common Stock | 11. COMMON STOCK [a] Authorized 150,000,000 authorized common voting shares, par value of $0.001, and 5,000,000 preferred shares, par value of $0.001. [b] Issued and outstanding shares Purchase Agreement and Financing with Lincoln Park Capital On September 14, 2017 we and Lincoln Park Capital Fund, LLC, or LPC, entered into a share and unit purchase agreement, which was amended on March 12, 2020, or the Purchase Agreement, pursuant to which we have the right to sell to LPC up to $11.0 million in shares of our common stock, par value $0.001 per share, subject to certain limitations and conditions set forth in the Purchase Agreement. On May 22, 2018 we obtained the requisite stockholder authorization to sell shares of our common stock to LPC in excess of 20% of our outstanding shares of common stock (as of the date we entered into the Purchase Agreement) in order to be able to sell to LPC the full amount remaining under the Purchase Agreement. Pursuant to the Purchase Agreement, LPC initially purchased 32,895 of our units, or the Units, at a purchase price of $30.40 per unit, with each Unit consisting of (a) one share of our common stock and (b) one warrant to purchase one-quarter of a share of common stock at an exercise price of $34.96 per share, or Warrant. Each Warrant became exercisable six months following the issuance date until the date that is five years and six months after the issuance date and is subject to customary adjustments. The Warrants were issued only as part of the Units in the initial purchase of $1.0 million and no warrants shall be issued in connection with any other purchases of common stock under the Purchase Agreement. After the initial purchase, if our stock price is above $1.00, as often as every other business day over the 54-month term of the Purchase Agreement, and up to an aggregate amount of an additional $10.0 million (subject to certain limitations) of shares of common stock, we have the right, from time to time, in our sole discretion and subject to certain conditions to direct LPC to purchase up to 150,000 shares of common stock. The purchase price of shares of common stock pursuant to the Purchase Agreement will be based on prevailing market prices of common stock at the time of sales without any fixed discount, and we will control the timing and amount of any sales of common stock to LPC. As consideration for entering into the Purchase Agreement, we issued to LPC 12,352 shares of common stock in September 2017 and, in connection with the amendment of the Purchase Agreement in March 2020, we agreed to pay to LPC $0.1 million as an expense reimbursement. The consideration of 12,352 shares of our common stock were fair valued based on the closing price of our common stock as at the transaction date and recognized as part of offering expenses. During the twelve months ended December 31, 2019, we offered and sold 374,000 shares of our common stock pursuant to the Purchase Agreement with LPC for gross proceeds of approximately $0.8 million. Since entering into the Purchase Agreement, from September 14, 2017 through December 31, 2019, we offered and sold an aggregate of 557,378 shares of our common stock, including the 32,895 shares that were part of the initial purchase of Units. These aggregate sales resulted in gross proceeds to us of approximately $4.4 million and offering expenses of $0.5 million. June 2018 Public Offering On June 19, 2018, we completed an underwritten registered public offering, pursuant to which we sold 710,500 Class A Units at a price per unit of $4.00 and 9,158 Class B Units at a price per unit of $1,000. Each Class A Unit consisted of one share of our common stock and a warrant to purchase one share of common stock. Each Class B Unit consisted of one share of Series A Convertible Preferred Stock, par value $0.001 per share, convertible at any time at the holder’s option into 250 shares of common stock and warrants to purchase 250 shares of common stock. Each warrant was immediately exercisable, expires on the five-year anniversary of the date of issuance and is exercisable at a price per share of common stock of $4.00. Additionally, subject to certain exceptions, if, after the June 19, 2018, (i) the volume weighted average price of our common stock for each of 30 consecutive trading days, or the 2018 Measurement Period, which 2018 Measurement Period commences on June 19, 2018, exceeds 300% of the exercise price (subject to adjustments for stock splits, recapitalizations, stock dividends and similar transactions), (ii) the average daily trading volume for such 2018 Measurement Period exceeds $500,000 per trading day and (iii) certain other equity conditions are met, and subject to a beneficial ownership limitation, then we may call for cancellation of all or any portion of the warrants then outstanding. The Class A Units and Class B Units were not certificated and the shares of common stock, Series A Convertible Preferred Stock and warrants comprising such Units were immediately separable and were issued separately in the public offering. The Class A and B Units were offered by us pursuant to the registration statement on Form S-1 (File No. 333-224840), and each amendment thereto, which was initially filed with the SEC, on May 10, 2018 and declared effective by the SEC on June 14, 2018 and the registration statement on Form S-1 (File No. 333- 225649) filed by the us with the SEC pursuant to Rule 462(b) of the Securities Act of 1933 on June 14, 2018. In addition, pursuant to the Underwriting Agreement we entered into with Ladenburg Thalmann & Co. Inc., or the Underwriter, on June 15, 2018, we granted the Underwriter a 45 day option, or the 2018 Overallotment Option, to purchase up to 450,000 additional shares of common stock and/or warrants to purchase up to 450,000 shares of Common Stock solely to cover over-allotments. The 2018 Overallotment Option was exercised in full on June 18, 2018. The public offering raised total gross proceeds of $13.8 million and after deducting $1.6 million in underwriting discounts and commissions and offering expenses, we received net proceeds of $12.2 million The underwriting discounts and commissions and offering expenses have been charged against the gross proceeds. As of December 31, 2019, all 9,158 shares of the Series A Convertible Preferred Stock had been converted into 2,289,500 shares of common stock, and no shares of the Series A Convertible Preferred Stock remained outstanding. October 2018 Registered Direct Offering On October 3, 2018 we completed a registered direct offering, pursuant to which we sold 1,789,258 shares of common stock at a price per share of $3.1445. We also issued to the investors in a concurrent private placement unregistered warrants to purchase up to 0.5 shares of common stock for each share purchased in the registered direct offering with an exercise price of $3.1445 per share. The warrants were exercisable immediately upon issuance and will expire five years following the date of issuance. The registered direct offering raised total gross proceeds of $5.6 million, and after deducting approximately $0.6 million in placement agent fees and offering expenses, we received net proceeds of $5.0 million. The placement agent fees and offering expenses have been charged against the gross proceeds. At The Market Offering Agreement with H.C. Wainwright & Co., LLC On June 7, 2019, we entered into an At The Market Offering Agreement, or the Offering Agreement, with H.C. Wainwright & Co., LLC, as agent, or H.C. Wainwright, pursuant to which we may offer and sell, from time to time and at our election, through H.C. Wainwright shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $6.0 million. Pursuant to the Offering Agreement, H.C. Wainwright may sell the shares our common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act, including sales made by means of ordinary brokers’ transactions, including on The Nasdaq Capital Market, at market prices or as otherwise agreed with H.C. Wainwright. H.C. Wainwright will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares of common stock from time to time, based upon instructions from us, including any price or size limits or other customary parameters or conditions we may impose. We are not obligated to make any sales of the shares of common stock under the Offering Agreement. The offering of shares of common stock pursuant to the Offering Agreement will terminate upon the earliest of (a) the sale of all of the shares of common stock subject to the Offering Agreement, (b) the termination of the Offering Agreement by H.C. Wainwright or us, as permitted therein, or (c) June 7, 2022. We will pay H.C. Wainwright a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of shares of common stock and have agreed to provide H.C. Wainwright with customary indemnification and contribution rights. We will also reimburse H.C. Wainwright for certain specified expenses in connection with entering into the Offering Agreement. The Offering Agreement contains customary representations and warranties and conditions to the placements of the shares of common stock pursuant thereto. From June 7, 2019 to December 31, 2019 we did not offer any shares of our common stock for sale pursuant to the Offering Agreement. As of December 31, 2019, shares of our common stock having an aggregate value of approximately $6.0 million remained available for sale under the Offering Agreement. The offering expenses and fees have been deferred and will be charged against gross proceeds. December 2019 Public Offering On December 17, 2019, we completed an underwritten registered public offering, pursuant to which we sold, 9,577,504 Class A Units at a price per unit of $0.60 and 6,256 Class B Units at a price per unit of $999.60. Each Class A Unit consisted of one share of our common stock and a warrant to purchase one share of common stock. Each Class B Unit consisted of one share of Series B Convertible Preferred Stock, par value $0.001 per share, convertible at any time at the holder’s option into 1,666 shares of common stock, and warrants to purchase 1,666 shares of common stock. Each warrant was immediately exercisable, expires on the five year anniversary of the date of issuance and is exercisable at a price per share of common stock of $0.60, subject to adjustment in the event of subsequent equity sales of common stock or securities convertible into common stock for an exercise price per share less than the exercise price per share of the warrants then in effect, provided, however, that the exercise price of the warrants cannot be reduced to an amount less than $0.06 per share of common stock. Additionally, subject to certain exceptions, if, after December 17, 2019, (i) the volume weighted average price of the common stock for each of 30 consecutive trading days, or the 2019 Measurement Period, which 2019 Measurement Period commences on the closing date, exceeds 300% of the exercise price (subject to adjustments for stock splits, recapitalizations, stock dividends and similar transactions), (ii) the average daily trading volume for such 2019 Measurement Period exceeds $500,000 per trading day and (iii) certain other equity conditions are met, and subject to a beneficial ownership limitation, then the Company may call for cancellation of all or any portion of the warrants then outstanding. The Class A Units and Class B Units were not certificated and the shares of common stock, Series B Convertible Preferred Stock and warrants comprising such Units were immediately separable and were issued separately in the public offering. The Class A and B Units were offered by us pursuant to the registration statement on Form S-1 (File No. 333-234530), and each amendment thereto, which was initially filed with the SEC on November 6, 2019 and declared effective by the SEC on December 17, 2019. In addition, pursuant to the Underwriting Agreement we entered into with Ladenburg Thalmann & Co. Inc., or Ladenburg, on December 17, 2019, we granted Ladenburg a 45 day option, or the 2019 Overallotment Option, to purchase up to 3,000,000 additional shares of common stock and/or warrants to purchase up to 3,000,000 shares of common stock solely to cover over-allotments. The 2019 Overallotment Option was exercised in full on December 17, 2019. The public offering raised total gross proceeds of $13.8 million and after deducting $1.5 million in underwriting discounts and commissions and offering expenses, we received net proceeds of $12.3 million. The underwriting discounts and commissions and offering expenses have been charged against the gross proceeds. As of December 31, 2019, 5,135 shares of the Series B Convertible Preferred Stock had been converted into 8,554,910 shares of common stock, and 1,121 shares of the Series B Convertible Preferred Stock remained outstanding. Equity Award Issuances and Settlements During the year ended December 31, 2019, we did not issue any shares of common stock to satisfy stock option exercises and issued 5,134 shares of common stock to satisfy restricted stock unit settlements, compared with the issuance of no shares of common to satisfy stock option exercises and 5,354 shares of common stock to satisfy restricted stock unit settlements for the year ended December 31, 2018. [c] Stock options 2018 Equity Incentive Plan As of December 31, 2019, we had reserved, pursuant to the 2018 Equity Incentive Plan, or the 2018 Plan, 1,336,055 common shares for issuance upon exercise of stock options and settlement of restricted stock units by employees, directors, officers and consultants of ours, of which 732,000 were reserved for options currently outstanding and 604,055 were available for future equity grants. Under the 2018 Plan, we may grant options to purchase common shares or restricted stock units to our employees, directors, officers and consultants. The exercise price of the options is determined by our board of directors but will be at least equal to the fair value of the common shares at the grant date. The options vest in accordance with terms as determined by our board of directors, typically over three to four years for options issued to employees and consultants, and over one to three years for members of our board of directors. The expiry date for each option is set by our board of directors with a maximum expiry date of ten years from the date of grant. In addition, the 2018 Plan allows for accelerated vesting of outstanding equity awards in the event of a change in control. The terms for accelerated vesting, in the event of a change in control, is determined at our discretion and defined under the employment agreements for our officers and certain of our employees. 2017 Equity Incentive Plan As of December 31, 2019, we had reserved, pursuant to the 2017 Equity Incentive Plan, or the 2017 Plan, 272,660 common shares for issuance upon exercise of stock options, currently outstanding, by employees, directors and officers of ours. Upon the effectiveness of our 2018 Plan, we ceased granting equity awards under our 2017 Plan. Under the 2017 Plan, we granted options to purchase common shares or restricted stock units to our employees, directors, officers and consultants. The exercise price of the options was determined by our board of directors but was at least equal to the fair value of the common shares at the grant date. The options vest in accordance with terms as determined by our board of directors, typically over three to four years for options issued to employees and consultants, and over one to three years for members of our board of directors. The expiry date for each option was set by our board of directors with a maximum expiry date of ten years from the date of grant. In addition, the 2017 Plan allows for accelerated vesting of outstanding equity awards in the event of a change in control. The terms for accelerated vesting, in the event of a change in control, is determined at our discretion and defined under the employment agreements for our officers and certain of our employees. 2010 Performance Incentive Plan As of December 31, 2019, we had reserved, pursuant to the 2010 Performance Incentive Plan, or the 2010 Plan, 15,931 common shares for issuance upon exercise of stock options and settlement of restricted stock units by employees, directors, officers and consultants of ours, of which 5,923 were reserved for options currently outstanding and 10,008 were reserved for restricted stock units currently outstanding. Under the 2010 Plan we granted options to purchase common shares and restricted stock units to our employees, directors, officers and consultants. The exercise price of the options was determined by our board of directors and was at least equal to the fair value of the common shares at the grant date. The options vest in accordance with terms as determined by our board of directors, typically over three to four years for options issued to employees and consultants, and over one to three years for members of our board of directors. The expiry date for each option is set by our board of directors with a maximum expiry date of ten years from the date of grant. In addition, the 2010 Plan allows for accelerated vesting of outstanding equity awards in the event of a change in control. The terms for accelerated vesting, in the event of a change in control, is determined at our discretion and defined under the employment agreements for our officers and certain of our employees. ASC 718 Compensation – Stock Compensation We recognize expense related to the fair value of our stock-based compensation awards using the provisions of ASC 718. We use the Black-Scholes option pricing model as the most appropriate fair value method for our stock options and recognize compensation expense for stock options on a straight-line basis over the requisite service period. In valuing our stock options using the Black-Scholes option pricing model, we make assumptions about risk-free interest rates, dividend yields, volatility and weighted average expected lives, including estimated forfeiture rates of the options. The expected life was calculated based on the simplified method as permitted by the SEC’s Staff Accounting Bulletin 110, Share-Based Payment. We consider the use of the simplified method appropriate because of the lack of sufficient historical exercise data following the reverse merger of OncoGenex. The computation of expected volatility was based on the historical volatility of comparable companies from a representative peer group selected based on industry and market capitalization. The risk-free interest rate is based on a U.S. Treasury instrument whose term is consistent with the expected life of the stock options. In addition to the assumptions above, as required under ASC 718, management made an estimate of expected forfeitures and is recognizing compensation costs only for those equity awards expected to vest. Forfeiture rates are estimated using historical actual forfeiture rates. These rates are adjusted on a quarterly basis and any change in compensation expense is recognized in the period of the change. We have never paid or declared cash dividends on our common stock and do not expect to pay cash dividends in the foreseeable future. The estimated fair value of stock options granted in the respective periods was determined using the Black-Scholes option pricing model using the following weighted average assumptions:
|  | 2019 |  |  | 2018 |  |
Risk-free interest rates |  |  | 2.52 | % |  |  | 2.93 | % |
Expected dividend yield |  |  | 0 | % |  |  | 0 | % |
Expected life |  | 5.97 years |  |  | 5.68 years |  |
Expected volatility |  |  | 94.25 | % |  |  | 88.23 | % |
The weighted average fair value of stock options granted during the year ended December 31, 2019 was $1.33. The results for the periods set forth below included stock-based compensation expense in the following expense categories of the consolidated statements of loss (in thousands):
|  | Year ended |
|  | December 31, |
|  | 2019 |  |  | 2018 |
Research and development |  | $ | 364 |  |  | $ | 272 |
General and administrative |  |  | 837 |  |  |  | 582 |
Total stock-based compensation |  | $ | 1,201 |  |  | $ | 854 |
Options vest in accordance with terms as determined by our board of directors, typically over three or four years for employee and consultant grants and over one or three years for board of director option grants. The expiry date for each option is set by our board of directors with, which is typically seven to ten years. The exercise price of the options is determined by our board of directors but is at least equal to the fair value of the share at the grant date. Stock option transactions and the number of stock options outstanding are summarized below:
|  | Number of |  |  | Weighted |
|  | Optioned |  |  | Average |
|  | Common |  |  | Exercise |
|  | Shares |  |  | Price |
Balance, January 1, 2019 |  |  | 665,585 |  |  | $ | 15.65 |
Granted |  |  | 345,350 |  |  |  | 1.73 |
Forfeited |  |  | (352 | ) |  |  | 2,450.80 |
Balance, December 31, 2019 |  |  | 1,010,583 |  |  | $ | 10.05 |
The following table summarizes information about stock options outstanding at December 31, 2019 regarding the number of ordinary shares issuable upon: (1) outstanding options and (2) vested options. (1) Number of common shares issuable upon exercise of outstanding options:
|  |  |  |  |  |  |  |  |  | Weighted- |
|  |  |  |  |  |  |  |  |  | Average |
|  |  |  |  |  |  |  |  |  | Remaining |
|  |  |  |  |  | Weighted- |  |  | Contractual |
|  |  |  |  |  | Average |  |  | Life |
Exercise Prices |  | Number of Options |  |  | Exercise Price |  |  | (in years) |
$1.42 - $1.99 |  |  | 302,100 |  |  | $ | 1.42 |  |  |  | 9.08 |
$2.00 - $2.97 |  |  | 386,650 |  |  |  | 2.56 |  |  |  | 8.72 |
$2.98 - $3.37 |  |  | 167,750 |  |  |  | 3.37 |  |  |  | 8.57 |
$3.38 - $3.70 |  |  | 8,250 |  |  |  | 3 |  |  |  | 9 |
$3.71 - $16.46 |  |  | 35,000 |  |  |  | 4 |  |  |  | 9 |
$16.47 - $69.45 |  |  | 104,910 |  |  |  | 28.90 |  |  |  | 7.58 |
$69.46 - $206.25 |  |  | 2,190 |  |  |  | 186.98 |  |  |  | 5.57 |
$206.26- $1,286.45 |  |  | 853 |  |  |  | 465.93 |  |  |  | 4.47 |
$1,286.46 - $1,348.05 |  |  | 1,530 |  |  |  | 1,304.27 |  |  |  | 3.78 |
$1,348.06 - $1,960.20 |  |  | 1,350 |  |  |  | 1,605.51 |  |  |  | 1.62 |
|  |  | 1,010,583 |  |  | $ | 10.05 |  |  |  | 8.69 |
(2) Number common shares issuable upon exercise of vested options:
|  |  |  |  |  |  |  |  |  | Weighted- |
|  |  |  |  |  |  |  |  |  | Average |
|  |  |  |  |  |  |  |  |  | Remaining |
|  |  |  |  |  | Weighted- |  |  | Contractual |
|  |  |  |  |  | Average |  |  | Life |
Exercise Prices |  | Number of Options |  |  | Exercise Price |  |  | (in years) |
$1.42 - $1.99 |  |  | 34,826 |  |  | $ | 1.42 |  |  |  | 9.08 |
$2.00 - $2.97 |  |  | 162,076 |  |  |  | 2.56 |  |  |  | 8.72 |
$2.98 - $3.37 |  |  | 59,410 |  |  |  | 3.37 |  |  |  | 8.57 |
$3.38 - $3.70 |  |  | — |  |  |  | — |  |  |  | — |
$3.71 - $16.46 |  |  | — |  |  |  | — |  |  |  | — |
$16.47 - $69.45 |  |  | 63,144 |  |  |  | 28.90 |  |  |  | 7.58 |
$69.46 - $206.25 |  |  | 2,190 |  |  |  | 186.98 |  |  |  | 5.57 |
$206.26- $1,286.45 |  |  | 853 |  |  |  | 465.93 |  |  |  | 4.47 |
$1,286.46 - $1,348.05 |  |  | 1,530 |  |  |  | 1,304.27 |  |  |  | 3.78 |
$1,348.06 - $1,960.20 |  |  | 1,350 |  |  |  | 1,605.51 |  |  |  | 1.62 |
|  |  | 325,379 |  |  | $ | 22.93 |  |  |  | 8.43 |
As at December 31, 2019, and December 31, 2018, the total unrecognized compensation expense related to stock options granted was $1.8 million and $2.4 million, respectively, each of which is expected to be recognized into expense over a period of approximately 2.1 years. The estimated grant date fair value of stock options vested during the years ended December 31, 2019, 2018 and 2017 was $0.9 million, $1.0 million and $0.6 million, respectively. The aggregate intrinsic value of options exercised was calculated as the difference between the exercise price of the stock options and the fair value of the underlying common stock as of the date of exercise. The aggregate intrinsic value of options exercised for the years ended December 31, 2019, 2018 and 2017 was zero, zero and zero, respectively. At December 31, 2019, the aggregate intrinsic value of the outstanding options was zero and the aggregate intrinsic value of the exercisable options was zero. [d] Restricted Stock Unit Awards We grant restricted stock unit awards that generally vest and are expensed over a four-year period. We also grant restricted stock unit awards that vest in conjunction with certain performance conditions to certain executive officers and key employees. At each reporting date, we are required to evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision. For the years ended December 31, 2019, 2018 and 2017, $0.4 million, $0.2 million and $0.1 million, respectively, of stock based compensation expense was recognized related to these awards. The following table summarizes our restricted stock unit award activity during the year ended December 31, 2019:
|  |  |  |  |  | Weighted |
|  | Number |  |  | Average |
|  | of |  |  | Grant Date |
|  | Shares |  |  | Fair Value |
Balance, January 1, 2019 |  |  | 15,142 |  |  | $ | 30.53 |
Released |  |  | (5,134 | ) |  |  | 33.54 |
Balance, December 31, 2019 |  |  | 10,008 |  |  | $ | 28.99 |
As of December 31, 2019, we had approximately $0.2 million in total unrecognized compensation expense related to our restricted stock unit awards which is to be recognized over a weighted-average period of approximately 1.58 years. [e] Stock Warrants On May 30, 2019, we entered into a Warrant Exercise Agreement, or the Exercise Agreement, with Armistice Capital Master Fund, Ltd., or Armistice. Pursuant to the Exercise Agreement, Armistice exercised (i) outstanding warrants to purchase 270,313 shares of our common stock with an exercise price of $3.1445 per share issued as part of the October 2018 financing and (ii) outstanding warrants to purchase 837,500 shares of our common stock with an exercise price of $4.00 per share issued as part of the June 2018 financing, for aggregate exercise proceeds to us of approximately $4.2 million, or, collectively, the Warrant Exercise. As an inducement for the Warrant Exercise, we agreed to issue to Armistice a new warrant, exercisable for six years, to purchase up to 1,200,000 shares of our common stock at an exercise price of $4.50 per share, or the New Warrant. We also agreed to file a registration statement covering the resale of the shares underlying the New Warrant Shares. The New Warrant and the shares underlying the New Warrant were offered to Armistice in reliance upon the exemption provided by Rule 506 of Regulation D and Section 4(a)(2) of the Securities Act of 1933. Under ASC 260, the fair value of the New Warrant of $3.9 million was recognized into accumulated deficit on our consolidated balance sheet as at June 30, 2019. We determined the fair value of the New Warrant using the Black-Scholes pricing model with the following assumptions: stock price of $4.23, volatility of 97.16%, risk-free interest rate of 2.06% and expected term of six years. The following is a summary of outstanding warrants to purchase common stock at December 31, 2019:
|  | Total |  |  |  |  |  |  |
|  | Outstanding |  |  | Exercise |  |  |
|  | and |  |  | price per |  |  |
|  | Exercisable |  |  | Share |  |  | Expiration Date
(1) Series A-1 Warrants issued in April 2015 financing |  |  | 2,175 |  |  | $ | 264.0000 |  |  | October 2020
(2) Warrants issued in September 2017 financing |  |  | 8,224 |  |  | $ | 34.9600 |  |  | March 2023
(3) Warrants issued in June 2018 financing |  |  | 2,282,000 |  |  | $ | 4.0000 |  |  | June 2023
(4) Warrants issued in October 2018 financing |  |  | 624,313 |  |  | $ | 3.1445 |  |  | October 2023
(5) Warrants issued in May 2019 financing |  |  | 1,200,000 |  |  | $ | 4.5000 |  |  | May 2025
(6) Warrants issued in December 2019 financing |  |  | 23,000,000 |  |  | $ | 0.6000 |  |  | Dec 2024
For the twelve months ended December 31, 2019, 837,500 of the warrants issued in the June 2018 financing were exercised at a per unit price of $4.00, for proceeds of $3.4 million and 270,313 of the warrants issued in the October 2018 financing were exercised at a per unit price of $3.1445, for proceeds of $0.8 million. For the twelve months ended December 31, 2018, 330,500 of the warrants issued in the June 2018 financing were exercised at a per unit price of $4.00, for proceeds of $1.3 million. No warrants were exercised for the year ended December 31, 2017. As at December 31, 2019, all of our outstanding warrants are classified as equity. [f] 401(k) Plan We maintain a 401(k) plan. Our securities are not offered as an investment option. Our shares are prohibited for inclusion our 401(k) plan, as well as any match of our shares to employee contributions. [g] Loss per common share The following table presents the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share and share amounts):
|  | Years ended December 31, |
|  | 2019 |  |  | 208 |  |  | 2017 |
Numerator |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (16,395 | ) |  | $ | (12,687 | ) |  | $ | (10,583 | )
Denominator |  |  |  |  |  |  |  |  |  |  |  |
Weighted average number of common shares outstanding |  |  | 8,246,400 |  |  |  | 3,510,217 |  |  |  | 479,442 |
Basic and diluted net loss per common share |  | $ | (1.99 | ) |  | $ | (3.61 | ) |  | $ | (22.07 | )
As of December 31, 2019, a total of 28.1 million options, restricted stock units and warrants, respectively, have not been included in the calculation of potential common shares as their effect on diluted per share amounts would have been anti-dilutive.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration